Related Experiment Videos
[Estrogen use in systemic lupus erythematosus].
S Ketari1, O Cherif, F Boussema
1Service de médecine interne, hôpital-Habib-Thameur, 8, rue Ali-Ben-Ayed, 1008 Montfleury, Tunisie. s.ktari@lycos.com
Gynecologie, Obstetrique & Fertilite
|September 6, 2005
Summary
The use of exogenous estrogen in systemic lupus erythematosus (SLE) is controversial. While some studies suggest increased SLE incidence, recent data indicate hormone replacement therapy may not raise flare risk in SLE patients.
Area of Science:
- Rheumatology
- Endocrinology
- Immunology
Context:
- The relationship between exogenous estrogen and systemic lupus erythematosus (SLE) is debated.
- Estrogen's role in SLE initiation and maintenance requires clarification.
- Existing literature presents conflicting evidence regarding estrogen's impact on SLE.
Purpose:
- To review the literature on the safety of exogenous estrogens in SLE patients.
- To synthesize findings from studies published between 1970 and 2004.
- To assess the risk of SLE flares associated with hormone therapy.
Summary:
- Cohort studies indicate a potential increase in SLE incidence with oral contraceptives and hormone replacement therapy (HRT).
- However, recent retrospective studies suggest HRT does not elevate the risk of SLE flares.
- The interrupted Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) trial highlights the need for large prospective studies.
Impact:
- Informs clinical decisions regarding estrogen use in SLE patients.
- Identifies gaps in current research, emphasizing the need for robust, diverse prospective trials.
- Contributes to understanding the complex interplay between hormones and autoimmune diseases.